2016 PROGRAM TO ACCELERATE CLINICAL TRIALS (PACT) RFP
SPECIAL ANNOUNCEMENT – ADDITIONAL FUNDING AVAILABLE

The true test for new Alzheimer’s drugs is in human clinical trials. Numerous treatments for Alzheimer’s disease have been shown to be safe and to have some positive effect when tested in animal models of Alzheimer’s disease. However, many of these potentially successful treatments have not been brought to human trials because of the increased cost and risk at this stage of research.

The ADDF is responding to this problem through the Program to Accelerate Clinical Trials (PACT) and now has specially dedicated funding available to support larger clinical trial efforts in this space. The goal of this Request for Proposals (RFP) is to increase the number of innovative treatments tested in humans for Alzheimer’s disease, related dementias and cognitive aging. This program will fund biomarker-based pilot clinical trials for Alzheimer’s disease, Phase I safety testing and IND-enabling studies to accelerate new drugs into trials. Through this PACT RFP, the ADDF is also interested in supporting clinical biomarker development programs and biomarker-based trials to validate putative mechanisms of action for targeted pharmacological and non-pharmacological approaches to prevention.

FUNDING MECHANISMS

- **Academic Program** seeks to create and support innovative translational programs in academic medical centers and universities.

- **Biotechnology Program** helps to create new biotechnology companies, and to fund existing biotechnology companies, with programs dedicated to Alzheimer’s disease drug discovery. Funding is provided through program-related investments (PRIs) that require return on investment based upon scientific and/or business milestones.

Programs areas of particular interest include:

- **Repurposing** – Testing drugs approved for other indications in Alzheimer’s disease clinical trials. Proposals should be hypothesis driven and drugs chosen for testing should target a mechanism of action(s) common to both diseases.

- **Therapies addressing the following targets:** Energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury and the blood-brain barrier interface.

APPLICATION SUBMISSION GUIDELINES

The ADDF now has funding available to consider trials budgeted at up to $3 million+ per application. This increased funding will be available only for the first deadline of 2016. Multi-year proposals will be considered. Inquiries with the ADDF staff are encouraged to determine the Foundation’s interest prior to application. All applicants are required to complete an electronic
"Letter of Intent" (LOI) available through our website. LOIs are due at least 2 weeks before the application deadline and will be reviewed on a rolling basis. After review of the LOI, ADDF may invite a full application via email with a link to the electronic application form. The ADDF will attempt to make a determination of interest within 90 days of receipt of the application. Full application guidelines and further information can be found on our website (http://www.alzdiscovery.org).

**DEADLINES**
- March 18
- June 3
- September 2
- December 9

*Letter of Intent is due at least two weeks prior to deadline

**For program-related inquiries, please contact:**

Diana Shineman, PhD  
*Director, Scientific Affairs*  
Phone: 212-901-8007  
E-mail: dshineman@alzdiscovery.org

**For application submission inquiries, please contact:**

Dan Teng  
*Grants Assistant*  
Phone: 212-901-7998  
dteng@alzdiscovery.org